Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REal Life, Retrospective Study of BOrtezomib Use as secoND Treatment for Myeloma Patients Previously Exposed to Bortezomib-based Therapies as First Line

NCT02797041 is registered in ClinicalTrials.gov with IRCCS Centro di Riferimento Oncologico della Basilicata as lead sponsor.

NCT NCT02797041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02797041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REal Life, Retrospective Study of BOrtezomib Use as secoND Treatment for Myeloma Patients Previously Exposed to Bortezomib-based Therapies as First Line
Lead sponsor
IRCCS Centro di Riferimento Oncologico della Basilicata
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2015
Completion date
June 30, 2016
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma